Furat Cevdet, Dogan Riza, Ilhan Gokhan, Bayar Ekrem, Ozpak Berkan, Kara Hakan, Bozok Şahin
Department of Cardiovascular Surgery, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Department of Cardiovascular Surgery, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, Turkey.
Cardiovasc J Afr. 2017;28(3):191-195. doi: 10.5830/CVJA-2016-089. Epub 2016 Nov 10.
This prospective study aimed to investigate the effects of the selective angiotensin receptor antagonist, telmisartan, on microalbuminuria after coronary artery bypass surgery in patients with diabetes mellitus.
Patients were divided into two groups with block randomisation, using the sealed envelope technique: group T (telmisartan group) consisted of patients who received the angiotensin receptor blocking agent telmisartan 80 mg daily for at least six months in the pre-operative period; group N-T (non-telmisartan group) consisted of patients who received no telmisartan treatment. Clinical and demographic characteristics, operative and postoperative features, microalbuminuria and high-sensitivity C-reactive protein levels were compared.
Forty patients met the eligibility criteria for the study. The groups did not differ with regard to clinical and demographic characteristics, and operative and postoperative features. Microalbuminuria levels between the groups differed significantly in the pre-operative period, first hour postoperatively and fifth day postoperatively. C-reactive protein levels between the groups differed significantly on the fifth day postoperatively.
Telmisartan was useful for decreasing systemic inflammation and levels of urinary albumin excretion in patients who had type 2 diabetes mellitus and had undergone coronary artery bypass surgery.
这项前瞻性研究旨在调查选择性血管紧张素受体拮抗剂替米沙坦对糖尿病患者冠状动脉搭桥术后微量白蛋白尿的影响。
采用密封信封技术进行区组随机化，将患者分为两组：T组（替米沙坦组）由术前至少六个月每天接受80毫克血管紧张素受体阻断剂替米沙坦治疗的患者组成；非替米沙坦组（N-T组）由未接受替米沙坦治疗的患者组成。比较临床和人口统计学特征、手术及术后特征、微量白蛋白尿和高敏C反应蛋白水平。
40名患者符合该研究的入选标准。两组在临床和人口统计学特征、手术及术后特征方面无差异。术前、术后第一小时和术后第五天，两组间微量白蛋白尿水平差异显著。术后第五天，两组间C反应蛋白水平差异显著。
替米沙坦有助于降低2型糖尿病且接受冠状动脉搭桥手术患者的全身炎症反应和尿白蛋白排泄水平。
